E Fund Management Co., Ltd. Myovant Sciences Ltd. Transaction History

E Fund Management Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $80,668 - $90,706	3,357 Added 30.1%	14,510 $391,000
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $10,880 - $19,172	-938 Reduced 7.76%	11,153 $200,000
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $11,747 - $22,181	-1,510 Reduced 11.1%	12,091 $150,000
Q1 2022 May 12, 2022	BUY	$11.38 - $16.4 $154,779 - $223,056	13,601 New	13,601 $181,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.